Evidence map›Paper›PMID 35926587›Full record

Observational studyIndian heart journal

Association of country economy and socioeconomic factors on risk factor control for primary prevention of cardiovascular disease in patients with diabetes mellitus: Insights from the DISCOVER study.

Ali O Malik, Hungta Chen, Fengming Tang, Paul S Chan, Andrew Cooper, Marίlia B Gomes, Vittal Hejjaji, Linong Ji, Kamlesh Khunti, Mikhail Kosiborod and 6 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 8 countries.

Ali O MalikSaint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA. Electronic address: aomalik@saint-lukes.org.
Hungta ChenAstraZeneca, Gaithersburg, MD, USA.
Fengming TangSaint Luke's Mid America Heart Institute, Kansas City, MO, USA.
Paul S ChanSaint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
Andrew CooperAstraZeneca, Cambridge, UK.
Marίlia B GomesRio de Janeiro State University, Rio de Janeiro, Brazil.
Vittal HejjajiSaint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
Linong JiPeking University People's Hospital, Beijing, China.
Kamlesh KhuntiUniversity of Leicester, Leicester, UK.
Mikhail KosiborodSaint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA; The George Institute for Global Health and University of New South Wales, Sydney, Australia.
Antonio NicolucciCenter for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
Poghni A Peri-OkonnySaint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
Marina V ShestakovaEndocrinology Research Center, Diabetes Institute, Moscow, Russian Federation.
Jiten VoraRoyal Liverpool University Hospital, Liverpool, UK.
Hirotaka WatadaGraduate School of Medicine, Juntendo University, Tokyo, Japan.
Suzanne V ArnoldSaint Luke's Mid America Heart Institute, Kansas City, MO, USA; University of Missouri Kansas City, MO, USA.
University of Missouri–Kansas City · USSaint Luke's Hospital · USAstraZeneca (United Kingdom) · GBAstraZeneca (United States) · USCenter for Outcomes Research and Clinical Epidemiology · ITEndocrinology Research Center · RUJuntendo University · JPPeking University People's Hospital · CNUniversidade do Estado do Rio de Janeiro · BRUniversity of Leicester · GBUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe sought to describe global patterns in achievement of risk factor control for primary prevention in patients with T2D and explore the association of country's GNI/capita with risk factor control.

methodsThe DISCOVER study is a prospective, observational study of patients with T2D from 38 countries enrolled at initiation of second-line glucose-lowering therapy. We examined achievement of risk factor control (glycosylated hemoglobin <7%, blood pressure <140/90 mmHg, prescription of a statin) at 3 years among those without optimal control at baseline. Countries were stratified by gross national income (GNI)/capita, from 2017). We examined the impact of country GNI/capita with achievement of risk factor control.

findingsOur cohort included 9613 patients with T2D and without baseline cardiovascular disease (mean age 57.2 ± 8.7 years, 47.9% women). At baseline, 6354/7646 patients (83.1%) had suboptimal glucose control, 3449/9200 patients (37.5%) had suboptimal BP control, and 2800/4221 patients (66.7%) were not on an appropriate statin (sample sizes differed due to missing covariate data). Optimal control at 3 years of follow-up was achieved in 41% (glucose), 56% (blood pressure), and 29% (statins) of patients. There was significant variability in achievement of risk factor control across countries but no association between country GNI/capita with achievement of risk factor control (p > 0.08 for all).

interpretationIn a global, prospective study of patients with T2D, we found that cardiovascular risk factor control achievement was suboptimal despite 3 years of follow-up in specialized health care systems. Neither country-level nor patient-level socioeconomic factors fully explained this finding.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsAgedFemaleGlucoseHumansMaleMiddle AgedPrimary PreventionProspective StudiesRisk FactorsSocioeconomic FactorsGlucoseHydroxymethylglutaryl-CoA Reductase InhibitorsPrimary preventionRisk factor controlType 2 diabetes

Identifiers

PMID35926587
PMCPMC9647648
OpenAlexW4289525700

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.